![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
K Wassermann, J Markovits, C Jaxel, G Capranico, KW Kohn and Y Pommier
Division of Cancer Treatment, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892.
The effect of cyanomorpholinyldoxorubicin, morpholinyldoxorubicin, doxorubicin, and Actinomycin D were studied on purified mouse leukemia (L1210) DNA topoisomerases I and II. DNA unwinding and cross-linking were also studied. It was found that 1) morpholinyldoxorubicin, cyanomorpholinyldoxorubicin, and Actinomycin D (but not doxorubicin) stimulated DNA topoisomerase I-induced cleavage at specific DNA sites; 2) only doxorubicin and Actinomycin D stimulated DNA cleavage by DNA topoisomerase II; 3) at higher drug concentrations, DNA intercalators suppressed enzyme-mediated DNA cleavage induced by DNA topoisomerase I, as well as topoisomerase II; 4) only cyanomorpholinyldoxorubicin produced DNA-DNA cross-links; no DNA unwinding could be observed; and 5) DNA intercalation (unwinding) potency of morpholinyldoxorubicin was about 2-fold less than that of doxorubicin. The data indicate that some DNA intercalators are not only inhibitors of DNA topoisomerase II but act also on DNA topoisomerase I. The stabilization of cleavage intermediates by intercalators may have a common mechanism for DNA topoisomerase I and DNA topoisomerase II.
This article has been cited by other articles:
|
|
 |
|
  B. W. Robinson, N.-K. V. Cheung, C. P. Kolaris, S. C. Jhanwar, J. K. Choi, N. Osheroff, and C. A. Felix Prospective tracing of MLL-FRYL clone with low MEIS1 expression from emergence during neuroblastoma treatment to diagnosis of myelodysplastic syndrome Blood, April 1, 2008; 111(7): 3802 - 3812. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Antony, K. K. Agama, Z.-H. Miao, M. Hollingshead, S. L. Holbeck, M. H. Wright, L. Varticovski, M. Nagarajan, A. Morrell, M. Cushman, et al. Bisindenoisoquinoline Bis-1,3-{(5,6-dihydro-5,11-diketo-11H-indeno[1,2-c]isoquinoline)-6-propylamino}propane bis(trifluoroacetate) (NSC 727357), a DNA Intercalator and Topoisomerase Inhibitor with Antitumor Activity Mol. Pharmacol., September 1, 2006; 70(3): 1109 - 1120. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Napoli, A. Valenti, V. Salerno, M. Nadal, F. Garnier, M. Rossi, and M. Ciaramella Reverse Gyrase Recruitment to DNA after UV Light Irradiation in Sulfolobus solfataricus J. Biol. Chem., August 6, 2004; 279(32): 33192 - 33198. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Mao, I. R. Mehl, and M. T. Muller Subnuclear distribution of topoisomerase I is linked to ongoing transcription and p53 status PNAS, January 17, 2002; (2002) 22631899. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Guano, P. Pourquier, S. Tinelli, M. Binaschi, M. Bigioni, F. Animati, S. Manzini, F. Zunino, G. Kohlhagen, Y. Pommier, et al. Topoisomerase Poisoning Activity of Novel Disaccharide Anthracyclines Mol. Pharmacol., July 1, 1999; 56(1): 77 - 84. [Abstract] [Full Text]
|
|
|
|
|
|
Y. Takebayashi, P. Pourquier, A. Yoshida, G. Kohlhagen, and Y. Pommier Poisoning of human DNA topoisomerase I by ecteinascidin 743, an anticancer drug that selectively alkylates DNA in the minor groove PNAS, June 22, 1999; 96(13): 7196 - 7201. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H.-M. Koo, M. Gray-Goodrich, G. Kohlhagen, M. J. McWilliams, M. Jeffers, A. Vaigro-Wolff, W. G. Alvord, A. Monks, K. D. Paull, Y. Pommier, et al. The ras Oncogene-Mediated Sensitization of Human Cells to Topoisomerase II Inhibitor-Induced Apoptosis J Natl Cancer Inst, February 3, 1999; 91(3): 236 - 244. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Kohlhagen, K. D. Paull, M. Cushman, P. Nagafuji, and Y. Pommier Protein-Linked DNA Strand Breaks Induced by NSC 314622, a Novel Noncamptothecin Topoisomerase I Poison Mol. Pharmacol., July 1, 1998; 54(1): 50 - 58. [Abstract] [Full Text]
|
|
|
|
|
|
M. Valenti, W. Nieves-Neira, G. Kohlhagen, K. W. Kohn, M. E. Wall, M. C. Wani, and Y. Pommier Novel 7-Alkyl Methylenedioxy-Camptothecin Derivatives Exhibit Increased Cytotoxicity and Induce Persistent Cleavable Complexes Both with Purified Mammalian Topoisomerase I and in Human Colon Carcinoma SW620 Cells Mol. Pharmacol., July 1, 1997; 52(1): 82 - 87. [Abstract] [Full Text]
|
|
|
|
|
|
N. Fujii, Y. Yamashita, T. Mizukami, and H. Nakano Correlation between the Formation of Cleavable Complex with Topoisomerase I and Growth-Inhibitory Activity for Saintopin-Type Antibiotics Mol. Pharmacol., February 1, 1997; 51(2): 269 - 276. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Bicknell, R. Snowden, and G. Cohen Formation of high molecular mass DNA fragments is a marker of apoptosis in the human leukaemic cell line, U937 J. Cell Sci., January 9, 1994; 107(9): 2483 - 2489. [Abstract] [PDF]
|
|
|
|
|
|
Y. Mao, I. R. Mehl, and M. T. Muller Subnuclear distribution of topoisomerase I is linked to ongoing transcription and p53 status PNAS, February 5, 2002; 99(3): 1235 - 1240. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
